Disease landscape
Ovarian Cancer
The GAP analysis revealed relatively modest limitations in access to ovarian cancer treatment and diagnosis in the Visegrad Group (V4) countries. Furthermore, there is relatively little variation in results between countries: the difference between the highest and lowest scores is 13 points. The main reason for the countries' unsatisfactory results is the limited access to registered drugs in the V4 countries, which translates into a suboptimal proportion of patients using PARP inhibitors.
Cross-Country
General GAP for Ovarian Cancer
Compliance with guidelines
Three ovarian cancer drugs had a positive recommendation in the clinical practice guidelines. Only 2 of them are available to OC patients in each of the V4 countries resulting in 67% of possible treatment compliance with the guidelines in the region.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
PARP inhibitors
Drug access
Number of patients treated (2023)
Drug access
Population treated (%)
Main issues
- The average time to reimbursement for ovarian cancer drugs in the V4 countries is 5.5 years. The difference between the shortest and the longest mean time to reimbursement among the coutriess is over 4.7 years.
- Overall, about half of the V4 ovarian cancer patients, potentially suitable for the PARP inhibitors, were actually treated with one of these drugs. Treatment coverage, however, varies greatly between the V4 countries from about 40% in Slovakia and Hungary, through about 50% in Czechia to over 75% in Poland.
- DALY (disability adjusted life-years) burden in most V4 countries is far above the European Union average. The only exception is Slovakia with the most recent DALY burden being exactly at the average EU level.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).